TDC
IMMU

Thompson Davis & Co’s Immunomedics Inc IMMU Stock Holding History

Thompson Davis & Co’s Portfolio IMMU Stock Details IMMU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$16K Hold
750
– – 0.03% 381
2018
Q2 		$18K Hold
750
– – 0.04% 339
2018
Q1 		$11K Hold
750
– – 0.03% 392
2017
Q4 		$12K Buy
750
+250
+50% +$2.95K 0.03% 395
2017
Q3 		$7K Sell
500
-250
-33% -$2.49K 0.01% 793
2017
Q2 		$7K Buy
+750
New +$5.27K 0.01% 775

Other funds holding IMMU

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Thompson Davis & Co's IMMU Position: Q3 2018 in Review

Thompson Davis & Co held its Immunomedics Inc (IMMU) position steady in Q3 2018 at 750 shares worth $16K. The position accounts for 0.03% of the portfolio, ranked #381.

Thompson Davis & Co first reported a position in IMMU in Q2 2017 and has held it in 6 quarters since. The position peaked at $18K in Q2 2018. 207 funds tracked by Wall St. Rank hold IMMU as of Q3 2018.

  • Thompson Davis & Co held 750 shares of Immunomedics Inc worth $16K as of Q3 2018.
  • Thompson Davis & Co left its Immunomedics Inc share count unchanged in Q3 2018.
  • Immunomedics Inc made up 0.03% of Thompson Davis & Co's portfolio in Q3 2018, its #381 holding.
  • Thompson Davis & Co first reported a position in Immunomedics Inc in Q2 2017 and has held it in 6 quarters since.
  • Thompson Davis & Co's Immunomedics Inc position peaked at $18K in Q2 2018.
  • 207 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.